Castle Biosciences, Inc. (NASDAQ:CSTL) Receives $42.00 Average Target Price from Analysts

Posted by George Bondi on Sep 17th, 2026

Shares of Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) have received an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $42.00.

Several brokerages have issued reports on CSTL. Zacks Research cut shares of Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 26th. Wall Street Zen raised shares of Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. Roth Capital began coverage on shares of Castle Biosciences in a research note on Wednesday, June 24th. They set a “buy” rating and a $40.00 price target on the stock. Robert W. Baird set a $36.00 price objective on shares of Castle Biosciences in a research report on Friday, July 31st. Finally, Weiss Ratings raised Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, July 31st.

Check Out Our Latest Report on Castle Biosciences

Insider Transactions at Castle Biosciences

In other news, COO Kristen Oelschlager sold 12,384 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $34.42, for a total value of $426,257.28. Following the completion of the sale, the chief operating officer directly owned 72,649 shares of the company’s stock, valued at $2,500,578.58. This trade represents a 14.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Derek J. Maetzold sold 20,356 shares of Castle Biosciences stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $31.11, for a total value of $633,275.16. Following the completion of the sale, the insider owned 21,479 shares in the company, valued at approximately $668,211.69. This trade represents a 48.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 182,358 shares of company stock valued at $5,571,471. Corporate insiders own 6.10% of the company’s stock.

Institutional Investors Weigh In On Castle Biosciences

Several institutional investors have recently made changes to their positions in CSTL. Global Retirement Partners LLC purchased a new position in shares of Castle Biosciences in the 2nd quarter valued at about $26,000. Caitong International Asset Management Co. Ltd grew its position in Castle Biosciences by 140.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,750 shares of the company’s stock worth $68,000 after buying an additional 1,022 shares during the period. Quantbot Technologies LP acquired a new position in Castle Biosciences during the second quarter worth about $62,000. Globeflex Capital L P acquired a new position in Castle Biosciences during the fourth quarter worth about $146,000. Finally, State of Wyoming purchased a new position in Castle Biosciences in the second quarter valued at about $117,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Castle Biosciences Stock Down 0.1%

CSTL stock opened at $35.48 on Monday. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -53.76 and a beta of 0.99. The company has a fifty day moving average price of $29.79 and a 200 day moving average price of $25.57. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85. Castle Biosciences has a 12 month low of $17.72 and a 12 month high of $44.28.

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.34. The company had revenue of $99.86 million for the quarter, compared to analyst estimates of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. Sell-side analysts expect that Castle Biosciences will post -1.29 earnings per share for the current year.

About Castle Biosciences

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians make more informed decisions about cancer diagnosis and treatment. Its products use genomic and molecular information to assess disease characteristics, patient risk and likely outcomes.

The company’s portfolio includes DecisionDx-Melanoma, which helps assess the risk of metastasis in patients with cutaneous melanoma; DecisionDx-SCC, which evaluates metastatic risk in certain patients with cutaneous squamous cell carcinoma; and MyPath Melanoma, which assists in distinguishing benign from malignant melanocytic lesions.